MX2013007067A - Anticuerpos anti-il-18 y sus usos. - Google Patents

Anticuerpos anti-il-18 y sus usos.

Info

Publication number
MX2013007067A
MX2013007067A MX2013007067A MX2013007067A MX2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A
Authority
MX
Mexico
Prior art keywords
antibodies
humanized
conjugates
interleukin
diagnosing
Prior art date
Application number
MX2013007067A
Other languages
English (en)
Inventor
Claire Dobson
Steven Lane
Philip Newton
Martin Schwickart
Ann-Charlott Steffen
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2013007067A publication Critical patent/MX2013007067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención proporciona anticuerpos humanos, humanizados y/o quiméricos, así como también fragmentos, derivados/conjugados y composiciones de los mismos con una afinidad de unión específica por la interleucina-18. La invención incluye el uso de estos anticuerpos para diagnosticar y tratar enfermedades asociadas con una actividad de la IL-18 aumentada, estando éstos en forma de una composición farmacéutica.
MX2013007067A 2010-12-20 2011-12-20 Anticuerpos anti-il-18 y sus usos. MX2013007067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424920P 2010-12-20 2010-12-20
PCT/EP2011/073496 WO2012085015A1 (en) 2010-12-20 2011-12-20 Anti-il-18 antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2013007067A true MX2013007067A (es) 2013-11-01

Family

ID=45372272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007067A MX2013007067A (es) 2010-12-20 2011-12-20 Anticuerpos anti-il-18 y sus usos.

Country Status (11)

Country Link
US (1) US9255144B2 (es)
EP (1) EP2655416A1 (es)
JP (1) JP2014508511A (es)
KR (1) KR20140003467A (es)
CN (1) CN103339147A (es)
AU (2) AU2011347354A1 (es)
BR (1) BR112013015508B1 (es)
CA (1) CA2822515C (es)
MX (1) MX2013007067A (es)
RU (1) RU2013133846A (es)
WO (1) WO2012085015A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2014080866A1 (ja) * 2012-11-21 2014-05-30 一般財団法人化学及血清療法研究所 新規なヒト抗ｉｌ－１８抗体
DK3041864T3 (da) * 2013-09-05 2021-09-27 Ab2 Bio Sa Il-18-bindende protein (il-18bp) ved inflammatoriske sygdomme
WO2015160795A1 (en) * 2014-04-14 2015-10-22 The Regents Of The University Of California Compositions and methods for treating inflammation
MY194040A (en) * 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN110382002A (zh) 2017-03-09 2019-10-25 Mab发现股份有限公司 特异性结合人il-1r7的抗体
WO2019213686A1 (en) * 2018-05-10 2019-11-14 The Council Of The Queensland Institute Of Medical Research Therapeutic compositions and uses therefor
JP6892180B2 (ja) 2018-12-03 2021-06-23 株式会社ｍＡｂＰｒｏｔｅｉｎ 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
CN109870570A (zh) * 2018-12-29 2019-06-11 广东云天抗体生物科技有限公司 一种检测猴il-18的酶联免疫试剂盒
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP4138917A1 (en) * 2020-06-01 2023-03-01 Avalo Therapeutics, Inc. Methods and treatment involving antibodies to il-18
CN112415191A (zh) * 2020-11-06 2021-02-26 郑州人福博赛生物技术有限责任公司 一种白细胞三烯检测试剂盒
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
WO2023121643A1 (en) * 2021-12-20 2023-06-29 Avalo Therapeutics, Inc. Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2351346C (en) 1998-12-10 2015-09-01 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
AU3944401A (en) 2000-03-31 2001-10-15 Cambridge Antibody Tech Improvements to ribosome display
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
ATE425186T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
RU2490278C2 (ru) * 2007-12-21 2013-08-20 Медиммун Лимитед ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
CA2713342A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2011347354A1 (en) 2013-08-01
BR112013015508B1 (pt) 2022-04-05
WO2012085015A9 (en) 2013-06-27
WO2012085015A1 (en) 2012-06-28
RU2013133846A (ru) 2015-01-27
BR112013015508A2 (pt) 2016-10-11
JP2014508511A (ja) 2014-04-10
EP2655416A1 (en) 2013-10-30
CN103339147A (zh) 2013-10-02
US9255144B2 (en) 2016-02-09
KR20140003467A (ko) 2014-01-09
AU2017201512A1 (en) 2017-03-23
CA2822515C (en) 2023-04-25
US20140004128A1 (en) 2014-01-02
CA2822515A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
MX357193B (es) Moleculas de union anti-alfa sinucleina.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX340295B (es) Anticuerpos monoclonales anti-c-met.
MX362039B (es) Anticuerpos anti-il-23.
EP3539988A3 (en) Monoclonal antibodies against her2
MX2020012426A (es) Anticuerpos anti-cd38.
WO2009083009A3 (en) Monoclonal antibodies against cd32b
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PH12014502406A1 (en) Anti-il-23p19 antibodies
AU2018256498A1 (en) Antibodies to amyloid beta
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
MY195289A (en) Anti IL-36R Antibodies
EP2582722A4 (en) ANTIBODIES AGAINST GD2
NZ728016A (en) Novel modulators and methods of use
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal